Additive manufacturing allows pharma and biotech companies to take advantage of 3D printing technology to produce medications ...
As GLP-1 therapies reshape obesity care, Brian Hilberdink, president of U.S. Human Pharma, Boehringer Ingelheim, argues that ...
Welcome to Pharmaceutical Executive Daily, your quick briefing on the top news shaping the pharmaceutical and life sciences ...
As Connecticut moves to rein in private equity's playbook in hospital deals, pharma and life sciences leaders face a parallel ...
A rare tumor launch using claims plus behavioral triggers and KOL-balanced content exceeded forecasts, attributing 60% of new ...
RayThera contributes multiple undisclosed-mechanism small-molecule immunology candidates positioned for broad applicability across immune-mediated indications, expanding modality diversity beyond ...
In today's Pharmaceutical Executive Daily, Biogen announces its second acquisition of 2026, a deal worth up to $1 billion for private immunology biotech RayThera, FDA approves Utebzi as the first and ...
Capvaxive uniquely adds eight adult-predominant invasive serotypes absent from other approved pneumococcal vaccines, positioning it to address serotype replacement gaps after routine pediatric PCV ...
FDA approved Utebzi, an oral carbapenem antibiotic developed by GSK in partnership with Spero Therapeutics, for the treatment of complicated urinary tract infections (cUTI) including pyelonephritis in ...
Kardigan’s offering proposes 23.3 million shares at $14–$16, targeting ~$350 million gross proceeds and an implied ~$1.3 ...
Silvia Taylor of Novavax details how the company leverages its expertise in vaccine development to build partnerships across ...
Strategic emphasis has shifted away from Novavax-led commercialization toward enabling partners with global scale, exemplified by Sanofi’s worldwide rights to market the COVID vaccine and Pfizer’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results